RESOLVE_trial_targeted_sequencing_data

RESOLVE: Abemaciclib + Letrozole +/_- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001711	This is a Phase II clinical trial. This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: - Abemaciclib (also known as Verzenio™) - Letrozole (also known as Femara®) - Metformin (also known as Glucophage®) - Zotatifin (also known as eFT226) - Gedatolisib (also known as PF-05212384)	Illumina NovaSeq 6000	15

Publications	Citations
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. Konstantinopoulos PA, Zhou N, Penson RT, Le TV, Campos S, Krasner C, Wright AA, Porter R, Horowitz N, Bouberhan S, Liu JF, Hindenach S, Sawyer H, Koppermann L, Hayes M, Polak M, Shea M, Widick P, Cheng SC, Castro C, Beumer JH, Matulonis UA, Lee EK. Nat Commun 17: 2025 395	0